Lipid risk factors of atherosclerosis: Who, when and how to treat?;Facteurs lipidiques de risque de l'atherosclerose: Qui traiter, quand et comment?

Annales d'Endocrinologie

Volumn 58, Issue 4, 1997, Pages 275-282

  Foubert, L ^a   Dejager, S ^a   Bruckert, E ^a   Turpin, G ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

cardiovascular disease; hyperlipidemia; lipid lowering therapy

Indexed keywords

'FRACTAL'; ANTILIPEMIC AGENT; BEZAFIBRATE; CIPROFIBRATE; COLESTYRAMINE; FENOFIBRATE; FISH OIL; FLUINDOSTATIN; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN A; PHENOFIBRATE; PRAVASTATIN; SIMVASTATIN; UNCLASSIFIED DRUG;

ATHEROSCLEROSIS; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; RISK FACTOR; SHORT SURVEY;

CHILD; CHOLESTEROL; CHOLESTEROL, HDL; CORONARY ARTERIOSCLEROSIS; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIAS; HYPERTRIGLYCERIDEMIA; MALE; MIDDLE AGED; RISK FACTORS; TRIGLYCERIDES;

EID: 0030792764     PISSN: 00034266     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (17)

1. BARTH JD, MANCINI GBJ. An update on lipid lowering therapy. Curr Op Lipidol 1995 ; 6 : 32-7.
2. BEMLIAN P. Génétique et dyslipidémies. éd. INSERM, Paris, 1996, 253 p.
3. BERG SCHMIDT E, DALBY KRISTENSEN S, DE CATERINA R, ILLINGWORTH DR. The effect of n-3 fatty acids on plasma lipids and lipoproteins and other cardiovascular risk factors in patients with hyperlipidemia. Atherosclerosis 1993 ; 103 : 107-21.
4. BERGLUND L. Diet and drug therapy for lipoprotein (a). Curr Op Lipidol 1995 ; 6 : 48-56.
5. BROWN WV, DUJOVNE CA, FARQUHAR JW. Effects of Fenofibrate on plasma lipids-double bind, multicenter study in patients with type IIa or IIb hyperlipidemia. Arteriosclerosis 1986 ; 6 : 670-8.
6. BRUCKERT E, DEJAGER S, CHAPMAN MJ. Ciprofibrate therapy normalises the atherogenic low-density-lipoprotein subspecies profile in combined hyperlipidemia. Atherosclerosis 1993 ; 100 : 91-102.
7. BRUCKERT E. Les hypertriglycéridémies. éd. John Libbey Eurotext, Paris, 1994, 172 pages.
8. BYINGTON RP, JUKEMA JW, SALONEN JT et al. Reduction in cardiovascular events during pravastatin therapy : pooled analysis of clinical events of the pravastatin atherosclerosis intervention program. Circulation 1995 ; 92 : 2419-25
9. FARNIER M, BONNEFOUS F, DEBBAS N, IRVINE A. Comparative Efficacy and Safety of Micronized Fenofibrate and Simvastatin in Patients with Primary Type IIa or IIb Hyperlipidemia. Arch Intern Med 1994 ; 154 : 441-9.
10. GROSSMAN M. A pilot study of ex vivo gene therapy for homozyaous familial hypercholesterolemia. Nature Medicine 1995 ; 11 : 1148-54.
11. LASUNCION MA, TERUEL JL, ALVAREZ JJ. Changes in lipoprotein (a), LDL-cholesterol and apolipoprotein B in homozygous familial hypercholesterolemic patients treated with dextran sulfate LDL-apheresis. Eur J Clin Invest 1993 ; 23 819-26.
12. SACKS FM, PFEFFER MA, MOYE LA et al. The effects of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996 ; 335 : 1001-9.
13. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4 444 patients with coronary heart disease : the Scandinavian Simvastatin Survival Study (4S). Lancet 1994 ; 344 : 1383-9.
14. SCHAEFER EJ, LAMONFAVA S, JENNER JL et al. Lipoprotein(a) levels and risk of coronary heart disease in men. The Lipid Research Clinics Coronary Primary Prevention Trial. JAMA 1994 ; 271 : 999-1003.
15. SHEPHERD J, COBBE SM, FORD I et al Prevention of coronary heart disease with pravastatine in men with hypercholesterolemia. N Engl J Med 1995 ; 333 1301-7.
16. SIMON A, LEVENSON J, Could the identification of subclinical atherosclerosis offer an alternative to the mass drug treatment of hypercholesterolemia ? Atherosclerosis 1994 ; 105 : 245-9.
17. TURPIN G, Pourquoi, quand, comment traiter les dyslipoprotéinémies ? Ed Fournier, Dijon, 1997, 250 p.